Preview

Rational Pharmacotherapy in Cardiology

Advanced search

AMLODIPINE ADVANTAGES IN ARTERIAL HYPERTENSION THERAPY

https://doi.org/10.20996/1819-6446-2008-4-5-53-56

Full Text:

Abstract

Aim. To study effects of calcium channel blocker, amlodipine on indices of ambulatory blood pressure monitoring (ABPM), heart rate variability, corrected QT-interval and its dispersion, structural and functional heart indices, microcirculation in patients with arterial hypertension (HT).

Material and methods. 48 patients with HT of 1-2 stages were involved in the study. After 2 week wash-out period amlodipine (5-10 mg/day) therapy was started. ABPM, 24 hour electrocardiogram monitoring, echocardiography, laser Doppler flowmetry was performed initially and in 24 weeks of therapy.

Results. Amlodipine therapy increased microcirculation efficacy, reduced repolarization nonhomogeneity, contributed to myocardial electrophysiological stability. Besides it improved structural and functional heart indices, decreased systolic and diastolic blood pressure (BP), reduced indices of BP load during a day.

Conclusion. Amlodipine is effective antihypertensive medicine, having prominent cardio- and vasoprotective effects and good tolerability.

About the Authors

V. M. Tsareva
Smolensk State Medical Academy, Krupskoy ul. 28, Smolensk, 214019 Russia
Russian Federation


N. J. Hozjainova
Smolensk State Medical Academy, Krupskoy ul. 28, Smolensk, 214019 Russia
Russian Federation


M. S. Bezaltynnyh
Smolensk State Medical Academy, Krupskoy ul. 28, Smolensk, 214019 Russia
Russian Federation


T. V. Brook
Smolensk State Medical Academy, Krupskoy ul. 28, Smolensk, 214019 Russia
Russian Federation


N. A. Borohova
Smolensk State Medical Academy, Krupskoy ul. 28, Smolensk, 214019 Russia
Russian Federation


I. E. Koltunov
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


N. M. Ahmedzhanov
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


References

1. Fox K., Garcia M.A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27(11):1341-81.

2. Freemantle N., Cleland J., Young P. et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.

3. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247(12):1707-14.

4. Yusuf S., Peto R., Lewis J. et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27(5):335-71.

5. Gibbons R.J., Chatterjee K., Daley J. et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33(7):2092-197.

6. Viskin S., Kitzis I., Lev E. et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25(6):1327-32.

7. Herlitz J., Dellborg M., Karlson B.W. et al. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther 2000;14(6):589-95.


For citation:


Tsareva V.M., Hozjainova N.J., Bezaltynnyh M.S., Brook T.V., Borohova N.A., Koltunov I.E., Ahmedzhanov N.M. AMLODIPINE ADVANTAGES IN ARTERIAL HYPERTENSION THERAPY. Rational Pharmacotherapy in Cardiology. 2008;4(5):53-56. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-5-53-56

Views: 1073


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)